AR011726A1 - Procedimiento para el tratamiento o prevencion del dolor y procesos y enfermedades inflamatorias, composicion farmaceutica, envase para uso en elmercado en dicho procedimiento - Google Patents

Procedimiento para el tratamiento o prevencion del dolor y procesos y enfermedades inflamatorias, composicion farmaceutica, envase para uso en elmercado en dicho procedimiento

Info

Publication number
AR011726A1
AR011726A1 ARP980102089A ARP980102089A AR011726A1 AR 011726 A1 AR011726 A1 AR 011726A1 AR P980102089 A ARP980102089 A AR P980102089A AR P980102089 A ARP980102089 A AR P980102089A AR 011726 A1 AR011726 A1 AR 011726A1
Authority
AR
Argentina
Prior art keywords
cox
acids
procedure
activity
prevention
Prior art date
Application number
ARP980102089A
Other languages
English (en)
Spanish (es)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR011726A1 publication Critical patent/AR011726A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
ARP980102089A 1997-05-05 1998-05-05 Procedimiento para el tratamiento o prevencion del dolor y procesos y enfermedades inflamatorias, composicion farmaceutica, envase para uso en elmercado en dicho procedimiento AR011726A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4563597P 1997-05-05 1997-05-05

Publications (1)

Publication Number Publication Date
AR011726A1 true AR011726A1 (es) 2000-08-30

Family

ID=21939053

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP980102089A AR011726A1 (es) 1997-05-05 1998-05-05 Procedimiento para el tratamiento o prevencion del dolor y procesos y enfermedades inflamatorias, composicion farmaceutica, envase para uso en elmercado en dicho procedimiento
ARP030101251A AR039628A2 (es) 1997-05-05 2003-04-09 Formulacion masticable de carprofeno, implante y composicion terapeutica

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP030101251A AR039628A2 (es) 1997-05-05 2003-04-09 Formulacion masticable de carprofeno, implante y composicion terapeutica

Country Status (32)

Country Link
EP (1) EP0988034A1 (fr)
JP (1) JP2000513020A (fr)
KR (2) KR20040004406A (fr)
CN (1) CN1255059A (fr)
AP (1) AP9801234A0 (fr)
AR (2) AR011726A1 (fr)
AU (1) AU6932198A (fr)
BG (1) BG103852A (fr)
BR (1) BR9808720A (fr)
CA (1) CA2288759A1 (fr)
DZ (1) DZ2479A1 (fr)
EA (1) EA003696B1 (fr)
GT (1) GT199800063A (fr)
HR (1) HRP980244A2 (fr)
HU (1) HUP0001286A3 (fr)
ID (1) ID21311A (fr)
IL (1) IL132570A0 (fr)
IS (1) IS5220A (fr)
MA (1) MA26491A1 (fr)
NO (1) NO995389L (fr)
NZ (1) NZ500183A (fr)
OA (1) OA11213A (fr)
PA (1) PA8450601A1 (fr)
PE (1) PE72599A1 (fr)
PL (1) PL337003A1 (fr)
SK (1) SK148199A3 (fr)
TN (1) TNSN98059A1 (fr)
TW (1) TW590773B (fr)
UY (1) UY24989A1 (fr)
WO (1) WO1998050033A1 (fr)
YU (1) YU55899A (fr)
ZA (1) ZA983722B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245797B1 (en) 1997-10-22 2001-06-12 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease
AU2003204888B2 (en) * 1998-05-22 2005-07-28 Pfizer Products Inc. Treating or Preventing the Early Stages of Degeneration of Articular Cartilage or Subchondral Bone in Mammals Using Carprofen and Derivatives
US6506785B2 (en) 1998-05-22 2003-01-14 Pfizer, Inc. Treating or preventing the early stages of degeneration of articular cartilage or subchondral bone in mammals using carprofen and derivatives
AU764872B2 (en) * 1998-10-23 2003-09-04 Merck Frosst Canada & Co. Combination product comprising an E-type prostaglandin ligand and a cox-2 selective inhibitor and methods of use
WO2000053149A2 (fr) * 1999-03-10 2000-09-14 G.D. Searle & Co. Procede et composition se rapportant a l'administration d'un inhibiteur de la cyclo-oxygenase-2
WO2001034204A1 (fr) * 1999-11-11 2001-05-17 Eli Lilly And Company Produits composes oncolytiques destines au traitement du cancer
JP2004521856A (ja) * 2000-05-15 2004-07-22 メルク フロスト カナダ アンド カンパニー Ｃｏｘ−２選択的阻害剤およびトロンボキサン阻害剤を用いる併用療法ならびにそのための組成物
RU2003100874A (ru) 2000-06-13 2004-06-27 Вайс (Us) Болеутоляющие и противовоспалительные составы, содержащие ингибиторы циклооксигеназы-2
DE10032132A1 (de) * 2000-07-01 2002-01-17 Lohmann Therapie Syst Lts Dermales Therapeutisches System enthaltend nichtsteroidale Antiphlogistika mit selektiver COX-2-Hemmung
US7189504B2 (en) 2000-08-07 2007-03-13 Vanderbilt University Compositions and methods for detecting and quantifying COX-2 activity and 2-arachidonylglycerol metabolites
US20040209959A1 (en) * 2001-07-16 2004-10-21 Edward Hogestatt Congeners of acetaminophen and related compounds as substrates for fatty acid conjugation and their use in treatment of pain, fever and inflammation
CA2519189C (fr) 2003-05-07 2012-07-17 Osteologix A/S Sels de strontium solubles dans l'eau pour le traitement de maladies des cartilages et/ou des os
KR100780983B1 (ko) * 2003-07-31 2007-11-30 파마시아 앤드 업존 캄파니 엘엘씨 소염제의 분산성 제제
WO2006123247A2 (fr) * 2005-05-20 2006-11-23 Pfizer Limited Combinaisons synergiques
WO2008122967A2 (fr) 2007-04-04 2008-10-16 Sigmoid Pharma Limited Composition pharmaceutique orale
WO2008132707A1 (fr) 2007-04-26 2008-11-06 Sigmoid Pharma Limited Fabrication de minicapsules multiples
US9278070B2 (en) 2009-05-18 2016-03-08 Sigmoid Pharma Limited Composition comprising oil drops
EP2464341B1 (fr) 2009-08-12 2022-07-06 Sublimity Therapeutics Limited Compositions immunomodulatrices comprenant une matrice polymère et une phase huileuse
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
DK3113774T3 (da) 2014-03-06 2022-03-07 Elanco Animal Health Incorporated Sammensætninger af grapiprant og fremgangsmåder til anvendelse deraf
EA036036B1 (ru) 2014-11-07 2020-09-16 Сигмойд Фарма Лимитед Композиции, содержащие циклоспорин
US12109218B2 (en) 2014-12-09 2024-10-08 Aratana Therapeutics, Inc. Compositions of grapiprant and methods for using the same
MX2017009011A (es) * 2015-01-09 2017-10-02 Jaguar Animal Health Metodos para tratar la diarrea en animales de compañia.
JP2023520367A (ja) * 2020-03-25 2023-05-17 エスアールアイ インターナショナル リポキシゲナーゼ阻害剤
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
KR102404883B1 (ko) 2020-11-30 2022-06-07 (주)이노보테라퓨틱스 벤즈브로마론을 포함하는 켈로이드 또는 비대흉터 예방 또는 치료용 약학 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896145A (en) * 1972-07-24 1975-07-22 Hoffmann La Roche Carbazoles
CA1319886C (fr) * 1987-02-03 1993-07-06 Alberto Ferro Solutions de micelles mixtes

Also Published As

Publication number Publication date
SK148199A3 (en) 2001-09-11
HRP980244A2 (en) 1999-02-28
JP2000513020A (ja) 2000-10-03
YU55899A (sh) 2003-08-29
HUP0001286A3 (en) 2000-12-28
KR20040004406A (ko) 2004-01-13
EA003696B1 (ru) 2003-08-28
AR039628A2 (es) 2005-03-02
BR9808720A (pt) 2000-07-11
PE72599A1 (es) 1999-08-12
NZ500183A (en) 2002-04-26
UY24989A1 (es) 2001-10-25
TNSN98059A1 (fr) 2005-03-15
CA2288759A1 (fr) 1998-11-12
KR20010012300A (ko) 2001-02-15
EP0988034A1 (fr) 2000-03-29
HUP0001286A2 (hu) 2000-11-28
IL132570A0 (en) 2001-03-19
ZA983722B (en) 1999-11-04
EA199900895A1 (ru) 2000-06-26
GT199800063A (es) 1999-10-26
WO1998050033A1 (fr) 1998-11-12
AU6932198A (en) 1998-11-27
OA11213A (en) 2003-07-14
PA8450601A1 (es) 2000-05-24
PL337003A1 (en) 2000-07-31
DZ2479A1 (fr) 2003-02-01
AP9801234A0 (en) 1999-11-04
TW590773B (en) 2004-06-11
NO995389D0 (no) 1999-11-04
MA26491A1 (fr) 2004-12-20
ID21311A (id) 1999-05-20
IS5220A (is) 1999-10-19
BG103852A (en) 2000-06-30
CN1255059A (zh) 2000-05-31
NO995389L (no) 2000-01-04

Similar Documents

Publication Publication Date Title
AR011726A1 (es) Procedimiento para el tratamiento o prevencion del dolor y procesos y enfermedades inflamatorias, composicion farmaceutica, envase para uso en elmercado en dicho procedimiento
TR200003583T2 (tr) Yeni 3-aril propiyonik asit türevleri ve benzerleri.
FR2395263A1 (fr) Derives d'acides thiadiazole-1, 2, 3 carboxyliques-5 utilisables comme matieres actives de produits herbicides
ES2159851T3 (es) Amidas de acidos aminotiofenocarboxilicos y su empleo como inhibidores de la fosfodiestearasa.
PT1039895E (pt) Utilizacao de acidos 3-benzoilfenilaceticos respectivos esteres ou amidas para o tratamento do glaucoma glc1a
DE69932414D1 (de) Indole-3-propionsäure, ihre salze und ester als arzneimittel
AR003938A1 (es) Compuestos triciclicos de urea utiles para la inhibicion de la funcion de la proteina g y para tratamiento de enfermedades proteoliticas, composicionfarmaceutica, y el uso de los mismos para la preparacion de medicamentos.
ES2120070T3 (es) Esteres nitricos dotados de una actividad anti-inflamatoria y/o analgesica y su procedimiento de preparacion.
ES2058024B1 (es) Nuevo derivado arilpropionico, procedimiento de fabricacion del mismo y su utilizacion como analgesico.
NO173046C (no) Fremgangsmaate for fremstilling av terapeutiske preparaterinneholdende 2-(2-fluor-4-bifenylyl)propionsyre
ATE50255T1 (de) Substituierte 9-fluor-3-methyl-7-oxo-2,3-dihydro7h-pyrido(1,2,3-de>(1,4>benzoxazin-6-carbonsaeur ; substituierte 5-amino-6-fluor-1,4-dihydro-4-oxochinolin-3-carbons|ure; substituierte 5-amino-6fluor-1,4-dihydro-4-oxo-1,8-naphthyridin-3- carbonsaeure; ihre derivate; diese enthaltende pharmazeutische zubereitungen und verfahren
ES2171933T3 (es) Derivados de androsteno.
BR9713178A (pt) Inbidores espirocìclicos da metaloprotease.
TR200200263T2 (tr) Yeni seçiçi retinoid agonistleri
Ventura-Martínez et al. Peripheral involvement of the nitric oxide–cGMP pathway in the indomethacin-induced antinociception in rat
AR000357A1 (es) Utilización de un antagonista de sustancia p para la preparación de una composición farmacéutica de aplicación topica para tratar las manchas rojas cutaneas de origen neurogeno y especialmente la rosacea y el eritema pudico
AR026257A1 (es) N-guanidinoalquilamidas, su preparacion, su uso y composiciones farmaceuticas que las contienen
Brune Prostaglandins and the mode of action of antipyretic analgesic drugs
PT880520E (pt) Derivados da benzo¬c|quinolizina sua preparacao e uso como inibidores da 5-alfa-reductase
ES2043943T3 (es) Procedimiento para la preparacion de compuestos con actividad analgesica central.
CO5021216A1 (es) Carprofeno selectivo para cox-2, para el tratamiento del dolor e inflamacion en perros
DE69711588D1 (de) Nimesulid enthaltende pharmazeutische zubereitung zur topischen anwendung
US4483854A (en) Systemic treatment of psoriasis using certain salicylates
GT199900171A (es) Concentrado oral de sertralina.
Peskar et al. Interaction of cyclooxygenase-2 inhibitors and salicylate in gastric mucosal damage

Legal Events

Date Code Title Description
FB Suspension of granting procedure